Dergiler / Balkan Medical Journal / 2013 / Cilt: 30 - Sayı: 1

Matrix metalloproteinase-9 level and gene polymorphism in sleep disordered breathing patients with or without cardiovascular disorders

Sayfa
8–12
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Finally, MMP-9 genotype was not associated with serum MMP-9 levels.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Obstructive sleep apnea syndrome (OSAS) is associated with increased cardiovascular morbidity and mortality.
📊
Temel Bulgular & Veri:We aimed to investigate the matrix metalloproteinase-9 (MMP-9) level and MMP-9 gene polymorphism in sleep apnea patients with or without cardiovascular disease.
💡
Sonuç & Katkı:Finally, MMP-9 genotype was not associated with serum MMP-9 levels.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Obstructive sleep apnea syndrome (OSAS) is associated with increased cardiovascular morbidity and mortality. We aimed to investigate the matrix metalloproteinase-9 (MMP-9) level and MMP-9 gene polymorphism in sleep apnea patients with or without cardiovascular disease. Study Design: Case-control study. Material and Methods: Two hundred nine patients [Mean age (±SD), 47 (±12) yrs; M/F, 170/39] diagnosed with sleep-disordered breathing were included in the study. Serum MMP-9 level was performed using enzyme-linked immunosorbant assay (ELISA) and MMP-9 gene polymorphism with polymerase chain reaction-restriction fragment length polymorphism. We divided the patient group into two subgroups: (1) patients with confirmed cardiovascular disease, i.e. CV-P Group and (2) patients without cardiovascular disease, CV-N Group. We compared all parameters between the two groups. Results: There were 56 OSAS patients with cardiovascular disorder (CV-positive group) and 153 OSAS patients without cardiovascular disorder (CV- negative group). CC, CT and TT genotype distributions between groups were similar [31 (55%), 25 (45%), 0 (0%) vs 88 (57%), 61 (40%), 4 (3%); respectively, p>0.05]. MMP-9 level was significantly higher in CV-P patients (442.7±139.3 pg/mL) than in CV-N patients (364.4±165.0 pg/mL; p=0.0018). Conclusion: Our results showed that the presence of MMP-9 polymorphism was not associated with cardiovascular disease. MMP-9 level was higher in OSAS patients with cardiovascular disorders than without cardiovascular disorders. Finally, MMP-9 genotype was not associated with serum MMP-9 levels.

🔖

Bu Makaleye Atıf Yap

YÜKSEL, M., VELİOĞLU, A. Ö., PELİN, Z., KUZU, H. O. (2022). Matrix metalloproteinase-9 level and gene polymorphism in sleep disordered breathing patients with or without cardiovascular disorders. Balkan Medical Journal, Cilt: 30 - Sayı: 1, 8–12. https://ajindex.com/articles/461556

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, et al. Sleep-disordered breathing and cardiovascular dis- ease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19-25
  2. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased in- cidence of cardiovascular disease in middle-aged men with ob- structive sleep-apnea: a 7-year follow up. Am J Respir Crit Care Med 2002;166:159-65. [CrossRef] 3. Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 2001;164:2147-65
  3. Brauer PR. MMPs role in cardiovascular development and dis- ease. Front Biosci 2006;11:447-78. [CrossRef] 5. Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, Saw- yer DB, et al. Regulations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004;109:2850-6. [CrossRef] 6. Ye S. Influence of matrix metalloproteinase genotype on car- diovascular disease susceptibility and outcome. Cardiovasc Res 2006;69:636-45. [CrossRef] 7. Wang L, Zhu T, Li Y. Relationship between matrix metalloprotein- ase-9 polymorphism and acute coronary syndrome. Journal of Nanjing Medical University 2007;21:147-50. [CrossRef] 8. Tazaki T, Minoguchi K, Yokoe T, Samson KT, Minoguchi H, Tanaka A, et al. Increased levels and activity of matrix metalloprotein- ase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2011;170:1354-9. [CrossRef] 9. Ye J, Liu H, Li Y, Liu X, Zhu J. Increased serum levels of C-reactive protein and matrix metalloproteinase-9 in obstructive sleep ap- nea syndrome. Chin Med J 2007;120:1482-6
  4. Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus-Santos JE. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 2005;365:183-7. [CrossRef] 11. The Report of American Academy of Sleep Medicine. Task Force Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;5:667-89
  5. Rechtschaffen A, Kales A (1968). A Manual of Standardized Ter- minology, Technique, and Scoring System for Sleep Stages of Hu- man Subjects, BIS/ BRI, UCLA, Los Angeles
  6. Öztürk L, Mansour B, Yüksel M, Yalçın AS, Çelikoğlu F, Gökhan N. Lipid peroxidation and osmotic fragility of red blood cells in sleep apnea patient. Clin Chim Acta 2003;33